Katherine A Janeway

Trials

Studies that name Katherine A Janeway as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:19 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT03213704 · Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)

  National Cancer Institute (NCI) · active not recruiting · Advanced Malignant Solid Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor · principal investigator
• Ph2
  NCT02470091 · Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma

  Children's Oncology Group · completed · Metastatic Osteosarcoma, Recurrent Osteosarcoma, Refractory Osteosarcoma · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 11:19 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• COG NCTN Network Group Operations Center
  U10CA180886 · NCI · COG RESEARCH FOUNDATION, LLC · PI Douglas S. Hawkins · fiscal years 2014 to 2026
  Named on NCT03213704, NCT02470091